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Abstract: We describe a new vaccination method called modiﬁ  ed vaccination technique 
(MVT). The technique is able to achieve downregulation of pathogenic autoimmune events 
leading to a chronic progressive disorder in rats called slowly progressive Heymann nephritis. 
Downregulation of immunopathological events is achieved by injections of immune complex 
(IC) made up of the target native antigen (ag) and speciﬁ  c naturally occurring immunoglobulin 
M (IgM) antibody (ab) directed against it. Repeated injections of IC maintain high levels 
of speciﬁ  c circulating IgM autoantibodies (aabs) against the kidney ag. The developing 
physiologic IgM aabs assist in the catabolism of both modiﬁ  ed and unmodiﬁ  ed renal ags from 
the circulation. No disease-causing renal ags in the circulation results in no stimulation of 
pathogenic immunoglobulin G aab producing cell lines. Such speciﬁ  c targeted therapy leads 
to termination of disease-causing processes and reestablishment of tolerance. The MVT can 
be employed both prophylactically and therapeutically with equal effectiveness. A redirected 
immune response is achieved by speciﬁ  cally stimulating the animals’ own IgM-producing cell 
lines with the injected ICs, resulting in a natural cure. Such ICs are nontoxic and nonirritant 
and cause no side effects. We surmise that the MVT, employing the appropriate components 
in each instance, can also be used to treat human ailments.
Keywords: antibody information transfer; autoimmune disease; immune complex; modiﬁ  ed 
vaccination technique; prophylactic; therapeutic 
Introduction
The reason why we cannot speciﬁ  cally treat experimental autoimmune disorders 
and naturally occurring autoimmune diseases in humans is that we still do not fully 
understand the autoimmune events that take place and contribute to the maintenance 
or loss of tolerance to self (Weigle et al 1967; Weir 1969; Tung 1994; Drakesmith et al 
2000; Manz et al 2002). Hence autoimmune diseases are still not treated speciﬁ  cally, 
but rather with immunosuppressive agents. Not only are immunosuppressive agents 
nonspeciﬁ  c in action, most often resulting in serious side effects, but they also fail to 
cure the disease, since the underlying pathogenic immune events can continue despite 
the control of symptoms (Ben Yehuda et al 1988; Golbus and McCune 1994).
It should be acknowledged that not every autoimmune process is harmful. In 
effect, most of the autoimmune process related events occurring throughout life are 
physiologic (Grabar 1965, 1983; Weir et al 1966; Weir 1966; Casali and Notkins 1989; 
Nawata et al 1990; Chen et al 1995). Physiologic autoimmune events contribute in a 
major way towards the catabolism of intracytoplazmic components released into the 
circulation from cells at the end of their life span. In a physiological sense, we are not per 
se “tolerant” to our intracytoplazmic components (Weir and Elson 1969), since speciﬁ  c 
immunoglobulin M (IgM) autoantibodies (aabs) are designated from birth to react with Biologics: Targets & Therapy 2007:1(1) 60
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these components and assist in their removal once they are 
released into the intravascular space (Solvason et al 1992). 
Such events prevent toxic accumulation of tissue breakdown 
products and/or their chemical modiﬁ  cation by intrinsic 
or foreign agents (Yung et al 1995). Chemically modiﬁ  ed 
autoantigens (aags) can initiate pathogenic autoimmune 
disease-causing responses (Totoritis and Rubin 1985).
The development of an autoimmune disease therefore 
results in most instances not from some malfunctioning 
of the immune system against normal self components but 
from abnormal presentation of self or self-like molecules to 
the cells of the immune system (ie, as modiﬁ  ed self or by 
molecular mimicry) (Barabas and Lannigan 1969; Fujinami 
and Oldstone 1985; Wilson et al 2000; Lenz et al 2001; 
Barabas et al 2004c). This thesis presumes that normal 
intracytoplazmic components will not produce autoimmune 
disease per se but in the meantime does not preclude 
their participation in lesion development. The following 
explanation will help to clarify these statements.
Issues relating to altered self 
antigen initiated events
If a native antigen (ag) from the target organ is exposed 
and becomes modiﬁ  ed, eg, by a chemical agent (Schoen 
and Trentham 1981; Totoritis and Rubin 1985; Yung et al 
1995; Rich 1996) in the intravascular space, or if a modiﬁ  ed 
self-like ag is administered repeatedly (Barabas et al 2003, 
2004c), then the following events can occur:
•  If the modiﬁ  ed ag initiated events are short-lived, then 
a limited pathogenic autoimmune disease process will 
result in minimal functional and morphological altera-
tions in the target organ (Totoritis and Rubin 1985).
•  If the modiﬁ  ed ag initiated events are maintained, then 
a progressive autoimmune disease process will ensue by 
the developing pathogenic immunoglobulin G (IgG) aabs 
and cause major morphological and functional change in 
the target organ resulting in a diagnosable autoimmune 
disease (Heymann et al 1959; Mendrick et al 1980).
Pathogenic autoimmune disease-causing events can take 
place because the pathogenic aab (resulting from the stimula-
tion of IgG aab producing cell lines by the modiﬁ  ed native 
ag) is able to cross-react with both native and modiﬁ  ed aags 
present in the circulation and in the target organ (eg, in the 
kidney it reacts with ﬁ  xed glomerular kidney ags and forms 
immune complexes (ICs) during the course of the autoim-
mune disease).
Genetic predisposition can also affect autoimmune 
disease development. Certain patients are unable to respond 
with sufﬁ  ciently strong immune responses to bacterial or 
viral infections. Under such circumstances, bacterial or viral 
breakdown products linger on at the site of infection, and 
sustained tissue damage occurs whereby cells are injured 
and intracytoplazmic components are released. In this 
local milieu the ideal conditions are thus created for the 
modiﬁ  cation of self ags. If a low-grade chronic infection 
persists, then pathogenic IgG aab production (occurring 
alongside IgM aab production) can commence. If such 
events are sufﬁ  ciently prolonged then serious morphologic 
and functional alterations can take place in the target organ 
and lead to a chronic progressive autoimmune disease 
(Wucherpfennig 2001).
Genetic susceptibility could also be due to physiologic 
immune response deficiency where an infection is not 
involved. For example, an individual’s immune system might 
be unable to produce sufﬁ  cient amounts of speciﬁ  c IgM aabs 
to clear released intracytoplazmic ags from the intravascular 
space; under such conditions aags can become modiﬁ  ed by 
agents (chemicals, drugs, toxic compounds, etc) present in the 
circulation and initiate pathogenic IgG aab response against 
the modiﬁ  ed self. If pathogenic IgG aabs are continuously 
produced then damage to a target organ can cause a low-grade 
slowly progressive autoimmune disease.
Issues relating to normal self ag 
initiated events
Although normal aags will not themselves produce an 
autoimmune disease, they can contribute to disease establish-
ment and progression for two reasons. First, the normal aags 
within an organ can become the primary targets of pathogenic 
autoimmune processes (Barabas et al 2004a), and second, 
they can contribute to IC deposits in affected organs (eg, in 
the glomeruli) (Barabas et al 2003).
In our studies we found that the physiologic IgM aabs 
and pathogenic IgG aabs cross-react with both normal and 
modiﬁ  ed ags (Barabas et al 2004b):
•  Pathogenic aabs reacting with normal aags in the target 
organ cause autoimmune disease (Barabas et al 2003), 
and when reacting with modiﬁ  ed aags in the circulation, 
maintain increased pathogenic IgG aab production.
•  Nonpathogenic IgM aabs also react with both native 
and modiﬁ  ed ags in the circulation and assist in their 
catabolism.
Heightened IgM aab production is maintained alongside 
IgG aab production during an autoimmune disease state both 
by native aags per se that are released into the intravascular 
space (Barabas et al 2003) and by developing ICs (made up Biologics: Targets & Therapy 2007:1(1) 61
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of native aags and speciﬁ  c IgM aabs). Thus, while patho-
genic IgG aab production attempts to increase the severity 
of insult against a target, there is a concurrent attempt by the 
IgM aabs to slow down pathogenic autoimmune processes 
(Barabas et al 2006c). 
Despite the normal functioning of the IgM mechanism, as 
long as the modiﬁ  ed ag is present and maintains pathogenic 
IgG aab production, tissue damage will proceed towards 
chronic progressive changes that result in morphological 
and functional alterations. But tipping the balance in favor 
of increased IgM aab production, in order to neutralize the 
circulating modiﬁ  ed and native ags that contribute to patho-
genesis, can halt the autoimmune disease altogether (Barabas 
and Lafreniere 2005).
Recent attempts to treat 
autoimmune disorders
So far research scientists have not come up with a speciﬁ  c 
immune-inducing technique that could prevent or treat 
endogenous source ag derived chronic ailments (such as 
autoimmune disorders and cancer). This might be due 
to the very complex science that describes autoimmune 
related diseases. Indeed, consensus as to the etiology and 
pathogenesis of autoimmune diseases still has not been 
reached (Tung 1994; Theofilopoulos 1995; Garza et al 
2000; Lernmark 2001; Ludewig et al 2001; Sherman 2001; 
Lafaille and Mathis 2002). Consequently, diverse opinions 
and research efforts continue to contribute to the probative 
and problem-solving work to find a cure. Under these 
circumstances the use of immunosuppressive agents is still 
advocated to treat patients with chronic ailments. In recent 
years treatment with monoclonal abs has achieved approval 
but most of such products are not speciﬁ  c in their action 
and cause side effects. Another treatment modality, the 
oral presentation of tissue-derived ags, has in experimental 
animals and even in humans with autoimmune disorders 
had a degree of beneﬁ  cial inﬂ  uence on autoimmune disease-
causing events, but has not resulted in a cure (Ramiya 
et al 1997; Weiner 1997, 2000; Faria and Weiner 1999; 
Bilsborough and Viney 2002).
The form of presentation of the target aag in producing 
(and also in preventing and treating) an autoimmune disorder 
can inﬂ  uence outcomes even to the extent of determining 
ﬁ  nal states of disease or no disease. A detailed schematic 
of the events involved is given in Figures 1 and 2. Under 
certain circumstances native aags and injected disease-
related ags can start or worsen disease progression (Peakman 
and Dayan 2001), for example when an aag released from 
the intracytoplazmic environment or an injected disease-
related ag is modiﬁ  ed by a modifying agent present in the 
individual’s intravascular space (Figure 3). Such modifying 
agents can be drugs (Yung and Richardson 1994) or their 
metabolic products, or toxic agents derived from infectious 
microbes etc (Guilherme and Kalil 2004). Peptides of 
microbial proteins, exhibiting sequence similarity or 
identity to self peptides through molecular mimicry 
(Wucherpfennig 2001), can also activate autoreactive 
T-cells and cause autoimmune disease. Under these unusual 
circumstances autoimmune disease-initiating processes can 
take place; however, under normal circumstances “native” 
intracytoplazmic ags liberated into the circulation will not 
cause pathogenic IgG aab response.
A new vaccination technique 
for the prevention and treatment 
of an experimental autoimmune 
kidney disease
Heymann nephritis (HN) and slowly progressive Heymann 
nephritis (SPHN) are pathogenic IgG aab initiated and medi-
ated autoimmune diseases (Heymann et al 1959; Barabas et al 
2004c). Classical HN is established in susceptible strains of 
rats by repeated IP injections of nephritogenic ags incorpo-
rated into Freund’s complete adjuvant [FCA] (Barabas and 
Lannigan 1969). After two to four injections of the prepara-
tion, progressive proteinuria, severe morphological changes in 
the kidney, and in the circulation pathogenic IgG aab against 
the brush-border region of the renal proximal convoluted 
tubules commences. Attempts to treat HN by various agents 
before or after the induction of the disease have proved to be 
unsuccessful (Barabas et al 1969, 1970; Kupor et al 1976; 
Cattran 1988; Matsukawa et al 1992; Penny et al 1998; 
Yokoyama et al 1999; Hasegawa et al 2001;). The futility of 
these attempts to downregulate immunopathological events 
has been due to at least two factors:
•  Kidney ag injected in FCA established an irreversibly 
progressive disease process with the development of 
pathogenic IgG aabs (Andres et al 1986).
•  Agents used to circumvent disease development or 
treat the progressive disease did not act speciﬁ  cally to 
achieve downregulation or termination of the ab-mediated 
response against kidney-directed immune insults 
(Barabas et al 1969, 1970; Baker et al 1989; Penny et al 
1998; Hasegawa et al 2001; Spicer et al 2001).
We realized that in order to inﬂ  uence immunopathological 
events we needed to establish a new model of HN that was Biologics: Targets & Therapy 2007:1(1) 62
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Figure 1 Autoimmune processes initiated and maintained by native and modiﬁ  ed autologous antigens.
Note: Autoimmune disease is initiated by pathogenic IgG aabs against modiﬁ  ed self (or by molecular mimicry). The cells of the individual’s immune system see the modiﬁ  ed 
self or self-like ags as exogenous (foreign-like) ags and respond accordingly to eliminate them with the developing IgG aabs. In the process of eliminating a particular aag 
major damage can occur by the pathogenic IgG aabs reacting with antigenic components in the target organ resulting in organ failure (brought about by morphological and 
functional changes) and even death. In order to reverse pathogenic autoimmune disease-causing events the following must take place: 
  1. Removal of the inciting agent that modiﬁ  es the autologous ags, if it can be identiﬁ  ed (it could be a drug, infectious agent etc);
  2. Increase in the speciﬁ  c IgM aab response against the target ags capable of removing both modiﬁ  ed and native ags from the circulation; or
  3. Preferably both 1 & 2.
“Native” aags initiate and maintain physiologic IgM aab response throughout life, assisting in the removal of intracytoplasmic aags released into the intravascular space.
Abbreviations: aab, autoantibody; aag, autoantigen; ag, antigen; AID, autoimmune disease; C, complement; IC, immune complex; IgG, immunoglobulin G; IgM, immunoglobulin 
M; MW, molecular weight.
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Figure 2 Possible fate of released autoantigens.
Note: Most of the time intracytoplazmic components released from damaged cells will be catabolized by physiological processes involving speciﬁ  c IgM aabs. However, when 
aags are altered, modiﬁ  ed aags can initiate and maintain disease-causing pathogenic aab production.
Abbreviations: aab, autoantibody; aag, autoantigen; IC, immune complex; IgG, immunoglobulin G; IgM, immunoglobulin M; MW, molecular weight.
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Aags are released from:   → normal and cancer cells: at the end of their life span. 
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slowly progressive. We established two models of SPHN. 
One was produced by using alum instead of FCA as the 
adjuvant in the injected renal ag (Barabas et al 2003). The 
other, which perhaps mimics most closely the development 
of a slowly progressive autoimmune disease in humans, was 
established by repeated injections of a chemically modiﬁ  ed 
renal ag preparation (Barabas et al 2004c). The two SPHN 
models illustrate the process by which immunological 
mishaps result in pathogenic autoimmune events that 
cause harm in target organs and lead to morphological and 
functional changes.
The next challenge was to ﬁ  nd a way to correct such 
immunological mishaps. To do so we have developed a new 
vaccination technique, and have successfully employed it 
in both SPHN models, before and after the initiation of the 
disease. This modiﬁ  ed vaccination technique (MVT), which 
Figure 3 Downregulation/upregulation of nonpathogenic and pathogenic autoimmune processes.
Note: Both physiologic and pathogenic autoimmune initiated and maintained events are regulated by the presentation of native and altered self-aags to the cells of the 
immune system. As shown, autoimmune disease-causing events can be accelerated as well as terminated by appropriate presentation of native aags.
Abbreviations: aab, autoantibody; ag, antigen; IC, immune complex; IgG, immunoglobulin G; IgM, immunoglobulin M; MW, molecular weight.
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is a hybrid of active and passive immunization programs, 
has proven itself capable of redirecting immune responses 
(Barabas et al 2004b, 2006b, 2006c).
In our SPHN experimental autoimmune disorder models, 
the MVT achieved specific downregulation of disease 
initiating and maintaining events (Figure 3). We produced 
speciﬁ  c ICs made up of the disease-causing native kidney 
tubular ag and speciﬁ  c IgM abs directed against it at slight ag 
excess (Barabas et al 2004b, 2006b, 2006c). Injections of these 
ICs at weekly intervals maintained high levels of circulating 
nonpathogenic IgM aabs. The increased production of IgM 
aabs neutralized both modiﬁ  ed and native ags by removing 
them from the circulation and preventing them from playing 
a part in pathogenic autoimmune events. Since the modiﬁ  ed 
ag was no longer available to stimulate pathogenic IgG aab 
production, the pathogenic IgG aab producing cell lines 
were silenced. The unmodiﬁ  ed (native) ag, normally located 
in the glomeruli of the kidney (Kerjaschki and Farquhar 
1983; Cornish et al 1984) and also present in the circulation 
(Makker and Singh 1982; Singh and Makker 1986; Singh and 
Schwartz 1986), did not remain a target of pathogenic aabs 
or a contributor to further deposition of IC. The absence of 
altered or native ags in the circulation meant downregulation 
of pathogenic autoimmune events (Figure 3).
We maintain that such downregulation of pathogenic 
autoimmune events can only be achieved with our MVT. The 
MVT is effective in both pre- and post-treatment protocols, 
ie, both in preventing autoimmune disease development 
(Barabas et al 2006b) and in terminating ongoing auto-
immune disease processes (Barabas et al 2004b, 2006c). 
The MVT, via the injection of ICs with predetermined 
immune inducing components, produces the same class of 
immunoglobulin (in our case speciﬁ  c IgM aabs directed 
against the nephritogenic ags both modiﬁ  ed and native) 
with the same speciﬁ  city against the target ag as resides in 
the inoculum. The technique provides a speciﬁ  c redirected 
immune response without inﬂ  uencing normal immune events 
in any way. The ICs are nontoxic and nonirritant in both 
short- and long-term applications. The technique achieves 
total downregulation of pathogenic autoimmune events 
resulting in regained tolerance. However, since memory 
cells are retained for pathogenic aab production, pathogenic 
autoimmune events could start up again if modiﬁ  ed ags are 
reintroduced. 
Summary and concluding remarks
Vaccination over the last 200 years has prevented the 
occurrence and spread of often lethal infectious and 
contagious diseases (diphtheria, small pox) in our population. 
However, in spite of vaccination’s development, many 
diseases initiated and maintained by exogenous ags (HIV/
AIDS, malaria, TB) and all of those caused by endogenous 
ags (autoimmune diseases, cancer) are still not controlled 
or treated either by prophylactic or therapeutic vaccination 
programs. Numerous attempts, especially within the last 
few years, attest to the desire to come up with effective 
vaccinations to deal with chronic ailments (Peakman 
and Dayan 2001; Schijns 2001; Andre 2003; Reed and 
Campos-Neto 2003; Slingluff, Jr. and Speiser 2005; Tang 
and Bluestone 2006). The fact that we still have not come 
up with speciﬁ  c vaccination technologies, despite enormous 
investments of money, manpower, government resources, etc, 
conﬁ  rms that the search for a cure is not easy. However, we 
are inching towards solutions. Lately there have been many 
publications that provide hope, not only for better drugs, but 
also for other treatment methods able to inﬂ  uence immune 
response outcomes (Peakman and Dayan 2001; Stauss 2001; 
Maloney et al 2002; Melief et al 2002; Morris et al 2003; 
Clynes 2005; Polakis 2005). We have substantial evidence 
demonstrating that a normally functioning immune system 
can exert protective immune responses against exogenous 
source ags (bacteria, viruses, etc) but often not so protective 
immune responses against harmful endogenous source ags. 
Sorting out physiologic and pathogenic immune activity 
against endogenous source ags – ie, events that can maintain, 
break, or reestablish tolerance – would provide us the 
chance to understand how to manipulate immune responses, 
eg, for tolerance reestablishment in an autoimmune disease. 
(In cancer, we would require the opposite. We would 
want a specific immune response against cells bearing 
cancer-speciﬁ  c ags, for the elimination of these cancer cells 
from the host’s internal environment). 
So far autoimmune diseases have been generally 
treated with immunosuppressive agents (Barabas et al 
1969, 1970; Bolton et al 1974; Cattran 1988). These 
medications nonspeciﬁ  cally suppress immune functions 
and predispose patients to infections. The aim in the last 
few years has been to ﬁ  nd better solutions or techniques to 
downregulate autoimmune disease-causing immune events. 
By observing the “natural” and “pathogenic” events that 
take place in normal and experimental autoimmune disease 
induced animals, one can investigate physiologic and 
pathogenic autoimmune responses in health and in disease. 
Extensive literature documents how aags released from the 
intracellular environment are assisted in their removal by 
speciﬁ  c IgM aabs (Weir et al 1966; Elson and Weir 1967; Biologics: Targets & Therapy 2007:1(1) 66
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Casali and Notkins 1989; Avrameas 1991; Chen et al 1995; 
Coutinho et al 1995; Barabas et al 2003). These aabs are 
physiologic and speciﬁ  c in their action against native and 
corresponding modiﬁ  ed native aags. Weir and associates 
have shown that speciﬁ  c naturally occurring IgM aabs play 
a signiﬁ  cant role in the catabolism of intracytoplazmic ags 
released from normal cells (Pinckard and Weir 1966; Weir 
et al 1966) at the end of their lifespan and following injury 
by cytotoxic and infectious agents, burns, hypoxia, trauma, 
etc. Such observations led naturally to the suggestion that 
these aabs played a role in the maintenance of tolerance to 
self ags (Weir and Elson 1969), ie, by efﬁ  ciently removing 
intracytoplazmic waste.
Several experiments have revealed promptly increased 
IgM aab production (since animals/humans are not per se 
“tolerant” to escaped intracytoplazmic cell components) 
following massive release of aags from the intracellular 
environment [secondary ab response] (Pinckard and Weir 
1966; Weir 1966; Barabas et al 2003). The elevated level of 
circulating IgM aabs assist in the removal of released aags. 
However, if the circulating released aags are not efﬁ  ciently 
cleared in the shortest possible time, they can become modi-
ﬁ  ed by agents present in the circulation such as drugs or their 
breakdown products, toxic agents, etc. In order to prevent 
toxic or modiﬁ  ed-self aag accumulation in the intravascular 
space, we can increase IgM aab production more effectively 
(ie, not relying on IgM aab stimulation by released aags 
alone) by administering ICs made up of aags and speciﬁ  c IgM 
abs directed against them at slight ag excess. These ICs, as 
mentioned above, will enhance the production of the same 
class of immunoglobulin with the same speciﬁ  city against 
the target ag as resides in the inoculum.
The implementation of our MVT is most appropriate 
during a pathogenic autoimmune event, such as in our 
experimental autoimmune kidney disease (Barabas et al 
2004b, 2006a, 2006b, 2006c), for the following reasons:
•  During an autoimmune disease process both pathogenic 
IgG aabs and nonpathogenic IgM aabs are produced. 
Pathogenic aabs cause harm and nonpathogenic aabs 
attempt to remove both native and modiﬁ  ed self ags 
thereby aiming to terminate autoimmune disease-causing 
events.
•  The pathogenic IgG aab production is maintained by 
modiﬁ  ed self-like ags.
•  The nonpathogenic IgM aab production is maintained by 
native aags.
•  Tipping the balance between IgG aab and nonpathogenic 
IgM aab production in favor of IgM aab response is 
achieved by injections of suitably assembled ICs made 
up of the target ag and speciﬁ  c IgM ab against it. The 
resulting increase in IgM aab in the circulation assists in 
the removal of both native and modiﬁ  ed ags and prevents 
further production of pathogenic IgG aabs.
•  In certain autoimmune diseases the inciting agent also 
has to be removed to achieve termination of pathogenic 
aab production.
We have shown that by redirecting an immune response 
we can prevent an experimental autoimmune kidney disease-
causing process from beginning (Barabas et al 2006b) and 
also terminate it with equal effectiveness when the disease 
is established (Barabas et al 2004b, 2006c). This solution 
is achieved by the MVT that we have developed. The 
vaccination technique can evoke a speciﬁ  c predetermined 
immune response of our choosing by stimulating appropriate 
ab-producing cell lines, as long as the appropriate vaccine 
components are present. The injected components are nontoxic 
and nonirritant and do not cause any disturbance in the normal 
functioning of the immune system. The MVT achieves by ab 
information transfer the production in the vaccinated recipients 
of the same class of immunoglobulin (ie, ab) with the same 
speciﬁ  city against the target ag as resides in the inoculum. 
According to our assessment, the immune system should be 
able to correct any mishaps that might occur (associated, eg, 
with autoimmune diseases, cancer, chronic infections, etc) 
provided the cells of the immune system are afforded the right 
presentation of the offending ag. 
We predict that this MVT will in time be the vaccina-
tion technique of choice for both the prevention and with 
equal effectiveness the treatment of most of the presently 
untreatable diseases caused by exogenous and endogenous 
source ags. 
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